

Connie B. Newman, MD FACP FAHA FAMWA
Adjunct Professor of Medicine, NYU School of Medicine
3 Red Fox Trail Warren, New Jersey 07059
Home: (732) 271-0205 Cell: (646) 725-8840
e-mail: connie.newman@nyumc.org
or cncbn@optonline.net

Curriculum Vitae

Education

Year	Degree	Field	Institution
1974	BA	Biology, Spanish	Wellesley College
1978	MD	Medicine	Weill Cornell Medical College

Internships and Residencies:

1978-79 Intern, Internal Medicine, Beth Israel Medical Center, New York, NY
1979-81 Resident, Internal Medicine, Beth Israel Medical Center, New York, NY

Postdoctoral Training:

1981-1984 Fellow in Endocrinology and Diabetes, Columbia University College of Physicians and Surgeons, New York, NY
1984-1985 Fellow in Endocrinology, New York University Medical Center, New York, NY

Licensure and Certification

1979 New York State License Registration No. 140599
9/16/1981 American Board of Internal Medical Certificate (no.79642)
11/08/1983 Subspecialty Board of Endocrinology and Metabolism (no. 079642)
4/29/2018-6/1/2028 American Board of Obesity Medicine (ID 89983844)

Academic Appointments

1984-1985 Teaching Assistant in Medicine
New York University School of Medicine, New York, NY
1985-1994 Assistant Professor of Medicine,
New York University School of Medicine, New York, NY
1994-1998 Associate Professor of Medicine (with tenure),
New York University School of Medicine, New York, NY
1998-2005 Adjunct Associate Professor of Clinical Medicine,
New York University School of Medicine, New York, NY
9/2007-1/2016 Adjunct Associate Professor of Clinical Medicine,
New York University School of Medicine, New York, NY
2/2016- Adjunct Professor of Medicine, New York University School of Medicine,
New York, NY

Hospital Appointments

1983-1984 Assistant Physician, Columbia University Medical Center, New York, NY
1985-1987 Associate Investigator, Dept of Veterans Affairs Medical Center, New York, NY
1988-1992 Research Associate, Dept of Veterans Affairs Medical Center, New York, NY
1985-1994 Assistant Attending in Medicine, Bellevue Hospital, New York, NY
1985-1994 Assistant Attending in Medicine, Tisch University Hospital, New York, NY
1992-1999 Consultant Attending in Medicine, Veterans Affairs Medical Center, New York, NY
1994-2005 Associate Attending in Medicine, Bellevue Hospital, New York, NY
1994-2005 Associate Attending in Medicine, Tisch University Hospital, New York, NY
9/2007- Consultant Attending Physician, Department of Veterans Affairs, New York Harbor Healthcare Center, New York, NY

Other Professional Positions and Visiting Appointments

1979-1980 Visiting Assistant Physician,
Rockefeller University Hospital, New York, NY
1980-1984 Visiting Associate Physician,
Rockefeller University Hospital, New York, NY
1998-2001 Director, Regulatory Affairs International,
Merck and Co., Rahway, New Jersey
2001-2003 Medical Director, Medical Regulatory Services
2003-2005 Senior Medical Director, Worldwide Medical
2005-2007 Executive Director and Regulatory Therapeutic Area Head for Cardiovascular
Diseases, Worldwide Regulatory Affairs and Quality Assurance
Pfizer Inc, New York, NY
2008- Academic Visitor, Nuffield Department of Population Health,
University of Oxford, Oxford, UK
3/2007-12/2014 Member, Tobert Medical Consulting, Warren, NJ
6/2015- Special Government Employee, FDA; Consultant to Endocrine and Metabolic
Drugs (EMDAC) Advisory Committee

Awards and Honors

1970 Valedictorian, Passaic High School, NJ
1970 National Merit Scholarship Program Finalist
1970 Samuel D. Joseph Literary Award
1973 Phi Beta Kappa
1973 Cervantes Prize, Wellesley College
1974 Durant Scholar, Wellesley College

1974	Trustee Scholar, Wellesley College
1981	Research Prize, Beth Israel Medical Center, New York, NY for research at Rockefeller University on acetaldehyde adducts of hemoglobin in alcoholic patients
2013	NYU Service Award for 25 years dedicated service to NYU Medical Center
2014	Commitment to Excellence Award, American Medical Women's Association
2015	Fellowship, American Medical Women's Association
2015	Fellowship, American College of Physicians
2016	Fellowship, American Heart Association
2017	Leadership Award, Endocrine Society
3/2018-3/2019	President, American Medical Women's Association

Major Committee Assignments

National/ (International) and Regional

2003-2005	Steering Committee, Collaborative Atorvastatin Diabetes Study (CARDS) (University College London, UK)
2003-2004	Steering Committee, Stroke Prevention by Aggressive Reduction in Cholesterol (SPARCL)
2011-2016	Steering Committee for BEST-D Trial: a randomized trial comparing the efficacy and safety of vitamin D 2000 IU/d, 4000 IU/d and Placebo (University of Oxford, Oxford, UK)
2013-2018	National Medical Committee, Planned Parenthood Federation of America, New York, NY
2015-	Special Government Employee, Endocrine Metabolic Drugs Advisory Committee (EMDAC), Food and Drug Administration (FDA)
2015-2018	Co-Chair, Fellowship Committee, American Medical Women's Association
2015-2017	Co-Chair, American Women's Hospital Service (supports international clinics and provides grants for medical students and residents to support their travel for medical work abroad)
2016-2018	Chair of American Heart Association Writing Group for Scientific Statement on Statin Safety and Statin Associated Adverse Events
2017-	Chair, Endocrine Society Clinical Practice Guideline for Management of Dyslipidemia in Endocrine Diseases

NYU School of Medicine

1983-1989	Subcommittee for Animal Studies, VA Hospital, New York, NY
-----------	--

Hospital

1980-1981	Committee on Scientific Activities, Beth Israel Medical Center, NY, NY
-----------	--

Memberships, Offices and Committee Assignments in Professional Societies

1983-	Endocrine Society
2012-2014	Member, Special Programs Committee, Endocrine Society
2014-2017	Chair, Special Programs Committee, Endocrine Society
2014-2017	Member, Scientific and Educational Programs Core Committee, Endocrine Society
2017-	Chair, Endocrine Society Clinical Practice Guideline for Management of Dyslipidemia in Endocrine Diseases
2017-	Member, Clinical Endocrine Update Steering Committee, Endocrine Society
1992-	American College of Physicians, NY Chapter
2018-	NY ACP Education Committee
2007-	Cholesterol Treatment Trialists Collaboration
2007-	American Heart Association (AHA); Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Council (primary), Lifestyle and Metabolic Health (secondary) Committee Assignments
2014-2016	Member, Women's Leadership Committee, ATVB Council, AHA
2015-2018	Member, Clinical Lipidology Committee, ATVB and Lifestyle Councils, AHA
2016-2018	Chair, AHA Scientific Statement: Statin Safety and Associated Adverse Events
2011-	American Medical Women's Association (AMWA) Committee Assignments
2014-	Obesity Section Lead, Preventive Medicine Task Force
2015-2017	Co-Chair, Preventive Medicine Task Force
2015-	Co-Chair, Fellowship Committee
2016-2017	Co-Chair, Membership Committee
2014-2017	Co-Chair, American Women's Hospital Service Committee
2018-	Co-Chair, Opioid Addiction in Women Task Force
2017-2018	President-elect
3/ 2018-3/30/2019	President
2014-	American Association of Clinical Endocrinologists (AACE) Committee Assignments
2014-2018	Lipid Committee

- 2014- **Obesity Society**
Committee Assignments
- 2016- Obesity Medical Education Collaborative
- 2014- **National Lipid Association (NLA)**
Committee Assignments
- 2015-2017 Continuing Medical Education (CME) Committee
2014-2015 Membership Committee
2014-2018 Graduate Medical Education Committee
- 2017- **Medical Women’s International Association (MWIA)**
Committee Assignments
- 2017-2019 Local Organizing Committee for July 2019 Centennial Meeting
2017-2019 Scientific Subcommittee for July 2019 Centennial Meeting

Editorial Positions

- Editorial Boards
1999-2002 Journal of Clinical Endocrinology and Metabolism

Principal Clinical and Hospital Service Responsibilities

- 1984-1998 Attending Physician Endocrinology and Diabetes Clinic, Veterans Administration Medical Center, New York, NY
- 1985-1998 Attending Physician Endocrinology and Diabetes Service, Bellevue Hospital and Veterans Administration Medical Center, New York, NY
- 2007-2018 Attending Physician, Endocrinology and Diabetes Clinic, Department of Veterans Affairs New York Harbor Healthcare Center
- 2018- Attending Physician, Weight Management Clinic, Department of Veterans Affairs New York Harbor Healthcare Center

Teaching Experience

- 1984-1998 Attending Physician Endocrinology and Diabetes Clinic, Veterans Administration Medical Center, New York, NY
- 1985-1998 Attending Physician, Endocrinology and Diabetes Service, Bellevue Hospital and Veterans Administration Medical Center, New York, NY

1986-1998 Endocrine Section Leader, Pathophysiology Course, New York University School of Medicine, New York, NY (8 hours per year)

2007- Attending Physician Endocrinology and Diabetes Clinic and Obesity Clinic, Department of Veterans Affairs New York Harbor Healthcare Center, New York, NY
Lectures on introduction to lipids, management of dyslipidemia, familial hypercholesterolemia, cardiovascular outcomes trials of statins, management of hypercholesterolemia, statin safety

Grants Received

1/85- 12/87 Veterans Administration Career Development Award, Associate Investigator (Principal Investigator), "The Role of the Pituitary Gland in Mammary Mitogenesis."

8/87 - 7/88 American Cancer Society Institutional Award, "The Role of Novel (non-hPRL, non-hGH) Human Pituitary Substances in Breast Cancer Growth." Co-investigator

7/88 - 6/92 Veterans Administration Career Development Award, Research Associate (Principal Investigator), "The Role of the Pituitary Gland in Mammary Mitogenesis."

Patents

None

Invited Seminars and Lectures

1996-1998: *Diagnosis and Management of Acromegaly*
Evaluation of Growth Hormone Deficiency in Adults
Location: various medical centers in the U.S.

Management of Prolactinomas
Location: AACE Annual Meeting

1998: Meet the Professor, *Management of Acromegaly*
Location: Endocrine Society Annual Meeting

2007- *Introduction to Lipids and Lipoproteins*
Reducing Cardiovascular Risk in Patients with Diabetes
Review of Cardiovascular Outcomes Trials of Statins
Managing Dyslipidemia with Statins and Fibrates
Familial Disorders of Lipid Metabolism

Familial Hypercholesterolemia
Hypertriglyceridemia: Etiology, Risks, and Treatment Strategies
Management of Hyperlipidemia in the Statin Intolerant Patient
Location: NY Harbor VA Hospital, Division of Endocrinology,
Diabetes and Metabolism

- March 2015 *Meet the Professor, Management of Hyperlipidemia in the Statin Intolerant Patient*, Endocrine Society Annual Meeting, San Diego
- March 2015 *Pathophysiology and Management of Obesity*, Centennial Meeting of the American Medical Women's Association, Chicago
- Sept. 2015 *Meet the Professor, The Statin Intolerant Patient*, Clinical Endocrinology Update Meeting, Miami
- February 5, 2016 *Evidence for Prevention of Cardiovascular Disease in Type 2 Diabetes Mellitus: Review of Cardiovascular Outcomes Trials*
Emirates Society of Endocrinology and Diabetes, Dubai
- February 6, 2016 *Debate: In defense of no targeted goals: a debate about the American 2013 ACC/AHA Guideline and the European guideline*
Emirates Society of Endocrinology and Diabetes, Dubai
- March 2016 *Hot Topics in Hypercholesterolemia: Are Statins as Effective in Women as in Men; PCSK9 Inhibitors*
AMWA 101st Annual Meeting, Miami
- Sept 11, 2016 *Statin Safety and Tolerability*
Endocrine Society Clinical Endocrinology Update, Seattle
- Dec 15, 2016 *Management of Hypercholesterolemia*
NYU Residents
- April 2017 *Meet the Professor: Statin Intolerance*
Annual Meeting of the Endocrine Society, Orlando, Florida
- May 2017 *Statin Safety and Intolerance*
NYU Fellows in Endocrinology
- June 2017 *New Frontiers in Women's Health: Challenges and Solutions for Obesity Prevention and Treatment*
Healthcare Business Women's Association, Women's Health Leadership Showcase Meeting, Rutgers University, Piscataway, NJ
- October 2017 *Obesity and its Effects on Reproductive Health: Region 2 Meeting of the American Medical Women's Association*, Albert Einstein,

Bronx, NY

- October 2017 *My Journey through Medicine: Weill Cornell Women in Medicine Group, NY, NY*
- March 2018 *Statin Safety and Tolerability: American Federation for Medical Research, Eastern Section, Philadelphia, PA*
- March 2018 *New Insights in Cardiovascular Disease Prevention in Diabetes. 103rd Annual Meeting of the American Medical Women's Association, Philadelphia, PA*
- September 2018 *Changing Directions: Non-traditional Career Paths, Weill Cornell Medicine/Columbia-Presbyterian Women in Medicine Conference, NY, NY*
- Sex Differences in Pain and Opioid Addiction, AMWA Region 2 Conference, Albert Einstein, Bronx, NY*
- April 2019 *Burnout and Resilience in Residents, American College of Physicians Annual Meeting, Philadelphia, PA*
- July 2019 *Sex Differences in Obesity, Centennial Meeting of the Medical Women's International Association, NY, NY*
- September 2019 *Alcohol Use in Midlife Women, Annual Meeting of the North American Menopause Society, Chicago, IL*

Military Service

None

Bibliography

Publications in Peer reviewed Journals

1. New MI, Baum CJ (maiden name), and Levine LS. Nomograms relating aldosterone excretion to urinary sodium and potassium in the pediatric population: their application to the study of childhood hypertension. Am J Cardiol 1976; 37: 658-666.
2. Stevens VJ, Fantl WJ, Newman CB, Sims RV, Cerami A, and Peterson CM. Acetaldehyde adducts with hemoglobin. J Clin Invest 1981; 67:361-369.
3. Newman CB, Levine LS, and New MI. Endocrine function in children with intrasellar and suprasellar neoplasms. Am J Dis Child 1981; 135:259-262.
4. Newman CB, Wardlaw SL, Van Vugt DA, Ferrin M, and Frantz AG. Adrenocorticotropin immunoactivity in monkey hypophyseal portal blood. J Clin Endocrinol Metab 1984; 56:108-112.
5. Cholst IN, Wardlaw SL, Newman CB, and Frantz AG. Prolactin response to breast stimulation in lactating women is not mediated by endogenous opiates. Am J Obstet Gynecol 1984; 150:558-561.
6. Newman CB, Wardlaw SL, and Frantz AG. Suppression of basal and stress-induced prolactin release and stimulation of luteinizing hormone secretion by alpha-melanocyte-stimulating hormone. Life Sciences 1985; 36:1661-1668.
7. Newman CB, Wardlaw SL, Stark RI, Daniel SS, and Frantz AG. Dopaminergic regulation of alpha-MSH and N-acetyl-beta endorphin secretion in the fetal lamb. Endocrinology 1987; 120:962-966.
8. Newman CB, Cosby H, Friesen HG, Feldman M, Cooper P, DeCrescito V, Pilon M, and Kleinberg DL. Evidence for a non-prolactin, non-growth hormone mammary mitogen in the human pituitary gland. Proc Natl Acad Sci (USA) 1987; 84:8110-8114.
9. Newman CB, Hurley AM and Kleinberg DL. Effect of CV 205-502 in hyperprolactinemic patients intolerant of bromocriptine. Clin Endocrinol 1989; 31:391-400.
10. Kleinberg DL, Ruan W, Catanese V, Newman CB and Feldman M. Non-lactogenic effects of growth hormone on growth and insulin-like growth factor I messenger ribonucleic acid of rat mammary gland. Endocrinol 1990; 126:3274-3276.
11. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook D, Malarkey WB, Jackson I, Vance ML, Thorner MO, Barkan A, Frohman LA, and Melmed S. Octreotide treatment of acromegaly: a multicenter double-blind placebo-controlled trial with long term efficacy studies. Ann Intern Med 1992; 117:711-718.

12. Ruan W, Newman CB, and Kleinberg DL. Intact and amino - terminally shortened forms of insulin-like growth factor-I induce mammary gland differentiation and development. Proc Natl Acad Sci USA 1992; 89: 10872-10876.

13. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF, Boyd AE, Sheeler L, Cook D, Malarkey WB, Jackson IMD, Vance ML, Thorner MO, Ho PJ, Jaffe CA, Frohman LA, and Kleinberg DL. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients-a clinical research center study. J Clin Endocrinol Metab 1995; 80:2768-2775.

14. Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, Veldhuis J, Dudley RE, Berman N, Davidson T, Barstow TJ, Sinow R, Alexander G, Swerdloff RS. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men---a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3654-3662.

15. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3034-3040.

16. Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 2003; 92: 670-676.

17. Newman CB, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006; 97: 61-67.

18. Leiter LA, Betteridge DJ, Chacra AR, Chait A, Ferannini E, Haffner SM, Kadovaki T, Tuomilehto J, Zimmet P, Newman CB, Hey-Hadavi J, Walkinshaw C on behalf of the AUDIT Steering Committee. AUDIT study. Evidence of global undertreatment of dyslipidaemia in patients with type 2 diabetes mellitus. Brit J Diab Vasc Disease 2006; 6:31-40.

19. Hitman GA, Colhoun H, Newman C, Szarek M, Betteridge DJ, Durrington PN, Fuller J, Livingstone S, Neil HAW, on behalf of the CARDS Investigators. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diab Med 2007; 24: 1313-1321.

20. Newman CB, Szarek M, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Demicco DA, Auster S, Fuller JH; CARDS Investigators. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diab Vasc Dis Res 2008; 5: 177-183.

21. Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem 2009; 55: 473-480.

22. Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2009; 52: 218-225.
23. Newman CB, Frisch KA, Rosenzweig B, Roubenoff R, Rey M, Kidder T, Kong Y, Pursnani A, Sedlis SP, Schwartzbard A, Kleinberg DL. Moderate doses of hGH improve lipids but not cardiovascular function in GH deficient adults with normal baseline cardiac function. J Clin Endocrinol Metab 2011; 96 (1): 122-132.
24. Cholesterol Treatment Trialists' (CTT) Collaboration. [Writing Committee: Emberson J, Kearney P, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech T, Collins R, Simes J, Baigent C.] Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE 2012; 7(1): e29849, doi:10.1371/journal.pone.0029849.
25. Newman CB, Carmichael JD, Kleinberg DL. Comparison of the effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a meta-analysis of placebo-controlled randomized trials. 2015. Pituitary 18: 297-305.
26. Stoes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgozoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, Marz W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN. Statin-associated muscle symptoms: impact on statin therapy. European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36 (17): 1012-1022
27. Clarke R, Newman C, Tomson J, Hin H, Kurien R, Cox J, Lay M, Sayer J, Hill M, Emberson J, Armitage J. Estimation of the optimum dose of vitamin D for disease prevention in older people: rationale, design and baseline characteristics of the BEST-D trial. Maturitas 2015; 80 (4): 426-431.
28. Newman CB, Tobert JA. Statin Intolerance: Reconciling clinical trials and clinical experience. 2015. JAMA 313 (10): 1011-1012.
29. Tobert JA, Newman CB. Statin tolerability: In defense of placebo-controlled trials. Eur J Prev Cardiol 2015 Aug 28 pii: 2047487315602861. [Epub ahead of print]
30. Tobert JA, Newman CB. Management of dyslipidemia for cardiovascular disease risk reduction (letter). Ann Int Med. 2016 164(7): 509
31. Newman CB, Tobert JA, Comment on the article by Moriarty et al. J Clin Lipidol 2016 10(1): 209-10.

32. deGoma E, Ahmad ZS, O'Brien E, Kindt I, Shrader P, Newman CB, Pokharel Y, Rader DJ, Moriarty PM, Gidding SS, Duell PB, Shapiro MD, Linton MF, Ballantyne CM, Duffy D, Baum SJ, Hemphill LC, Neal WA, Hudgins LC, Ahmed CD, Wilemon KA, Row MT, Knowles JW. LDL-C levels and treatment patterns among adults with heterozygous familial hypercholesterolemia in the United States: Data from the CASCADE-FH registry. 2016. *Circ Cardiovasc Genet*. 2016 Jun; 9(3): 240-9
33. Tobert JA and Newman CB The placebo effect in the context of statin intolerance. 2016 *J Clin Lipidology* 2016, 10: 739-47.
34. Ahmad ZS, Andersen RL, Andersen LH, O'Brien EC, Kindt I, Shrader P, Vasandani C, Newman CB, deGoma EM, Baum SJ, Hemphill LC, Hudgins LC, Ahmed CD, Kullo IJ, Gidding SS, Duffy D, Neal W, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Linton MF, Duell PB, Shapiro MD, Moriarty PM, Knowles JW. US Physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. *J Clin Lipidology* 2016; 10 (5): 1223-9.
35. Hin H, Tomson J, Newman C, Kurien R, Lay M, Cox J, Sayer J, Hill M, Emberson J, Armitage J, Clarke R. for the BEST-D Trial Collaborative Group. Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care. 2017 *Osteoporos Int* 28: 841-51.
36. Newman, CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuvver G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK; on behalf of the American Heart Association Clinical Lipidology, Lipoprotein Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin safety and associated adverse events: a scientific statement from the American Heart Association. *Arterioscler Thromb Vasc Bio*. 2019; 39:e38-e81.

Publications from the Cholesterol Treatment Trialists' Collaboration

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. . *Lancet*. 2005 Oct 8; 366 (9493):1267-78.
2. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet*. 2008 Jan 12; 371(9607):117-25.
3. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhalra N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and

safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13; 376 (9753):1670-81

Collaborators (137)

de Lemos J, Braunwald E, Blazing M, Murphy S, Downs JR, Gotto A, Clearfield M, Holdaas H, Gordon D, Davis B, Koren M, Dahlof B, Poulter N, Sever P, Knopp RH, Fellström B, Holdaas H, Jardine A, Schmieder R, Zannad F, Goldbourt U, Kaplinsky E, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Fuller J, Neil A, Wanner C, Krane V, Sacks F, Moyé L, Pfeffer M, Hawkins CM, Braunwald E, Barter P, Keech A, Tavazzi L, Maggioni A, Marchioli R, Tognoni G, Franzosi MG, Maggioni A, Bloomfield H, Robins S, Collins R, Armitage J, Keech A, Parish S, Peto R, Sleight P, Pedersen TR, Ridker PM, Holman R, Meade T, Simes J, Keech A, MacMahon S, Marschner I, Tonkin A, Shaw J, Serruys PW, Nakamura H, Knatterud G, Furberg C, Byington R, Macfarlane P, Cobbe S, Ford I, Murphy M, Blauw GJ, Packard C, Shepherd J, Kjekshus J, Pedersen T, Wilhelmsen L, Braunwald E, Cannon C, Murphy S, Collins R, Armitage J, Bowman L, Parish S, Peto R, Sleight P, Baigent C, Baxter A, Collins R, Landray M, La Rosa J, Rossouw J, Probstfield J, Shepherd J, Cobbe S, Macfarlane P, Ford I, Flather M, Kastelein J, Newman C, Shear C, Tobert J, Varigos J, White H, Yusuf S, Mellies M, McGovern M, Barclay J, Belder R, Mitchel MY, Musliner T, Ansquer JC, Llewellyn BM, Bortolini M, Brandrup-Wognsen G, Bryzinski B, Olsson G, Pears J, DeMicco D, Baxter A, Baigent C, Barnes EH, Bhala N, Blackwell L, Buck G, Collins R, Emberson J, Herrington WG, Holland LE, Kearney PM, Keech A, Kirby A, Lewis DA, Marschner I, Pollicino C, Reith C, Simes J, Sourjina T

4. Cholesterol Treatment Trialists' (CTT) Collaboration, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech A, Collins R, Simes J, Baigent C. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7(1):e29849. doi: 10.1371/journal.pone.0029849. Epub 2012 Jan 19.

Collaborators (125)

de Lemos J, Braunwald E, Blazing M, Murphy S, Downs JR, Gotto A, Clearfield M, Holdaas H, Gordon D, Davis B, Koren M, Dahlof B, Poulter N, Sever P, Knopp RH, Fellström B, Holdaas H, Jardine A, Schmieder R, Zannad F, Goldbourt U, Kaplinsky E, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Fuller J, Neil A, Wanner C, Krane V, Sacks F, Moyé L, Pfeffer M, Hawkins CM, Braunwald E, Kjekshus J, Wedel H, Wikstrand J, Tavazzi L, Maggioni A, Marchioli R, Tognoni G, Franzosi MG, Maggioni A, Collins R, Armitage J, Keech A, Parish S, Peto R, Sleight P, Pedersen TR, Ridker PM, Simes J, Keech A, MacMahon S, Marschner I, Tonkin A, Shaw J, Serruys PW, Nakamura H, Knatterud G, Furberg C, Byington R, Macfarlane P, Cobbe S, Ford I, Murphy M, Blauw GJ, Packard C, Shepherd J, Kjekshus J, Pedersen T, Wilhelmsen L, Braunwald E, Cannon C, Murphy S, Collins R, Armitage J, Bowman L, Parish S, Peto R, Sleight P, La Rosa J, Shepherd J, Cobbe S, Macfarlane P, Ford I, Flather M, Kastelein J, Newman C, Shear C, Tobert J, Varigos J, White H, Yusuf S, Baxter A, Baigent C, Barnes EH, Bhala N, Blackwell L, Buck G, Collins R, Emberson J, Herrington WG, Holland LE, Kearney PM, Keech A, Kirby A, Lewis DA, Marschner I, Reith C, Simes J, Mellies M, McGovern M, Barclay J, Belder R, Mitchell

Y, Musliner T, Ansquer JC, Llewellyn M, Bortolini M, Bryzinski B, Olsson G, Pears J, DeMicco D.

5. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012 Aug 11;380 (9841):581-90. **Collaborators (139)**

de Lemos J, Braunwald E, Blazing M, Murphy S, Downs JR, Gotto A, Clearfield M, Holdaas H, Gordon D, Davis B, Koren M, Dahlof B, Poulter N, Sever P, Knopp RH, Fellström B, Holdaas H, Jardine A, Schmieder R, Zannad F, Goldbourt U, Kaplinsky E, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Fuller J, Neil A, Wanner C, Krane V, Sacks F, Moyé L, Pfeffer M, Hawkins CM, Braunwald E, Kjekshus J, Wedel H, Wikstrand J, Barter P, Keech A, Tavazzi L, Maggioni A, Marchioli R, Tognoni G, Franzosi MG, Maggioni A, Bloomfield H, Robins S, Collins R, Armitage J, Keech A, Parish S, Peto R, Sleight P, Pedersen TR, Ridker PM, Holman R, Meade T, Simes J, Keech A, MacMahon S, Marschner I, Tonkin A, Shaw J, Serruys PW, Nakamura H, Knatterud G, Furberg C, Byington R, Macfarlane P, Cobbe S, Ford I, Murphy M, Blauw GJ, Packard C, Shepherd J, Kjekshus J, Pedersen T, Wilhelmsen L, Braunwald E, Cannon C, Murphy S, Collins R, Armitage J, Bowman L, Parish S, Peto R, Sleight P, Baigent C, Landray M, Collins R, La Rosa J, Rossouw J, Probstfield J, Shepherd J, Cobbe S, Macfarlane P, Ford I, Flather M, Kastelein J, Newman C, Shear C, Tobert J, Varigos J, White H, Yusuf S, Mellies M, McGovern M, Barclay J, Belder R, Mitchel Y, Musliner T, Ansquer JC, Llewellyn M, Bortolini M, Brandrup-Wognsen G, Bryzinski B, Olsson G, Pears J, DeMicco D, Baigent C, Barnes EH, Baxter A, Bhala N, Blackwell L, Buck G, Collins R, Emberson J, Herrington WG, Holland LE, Kearney PM, Keech A, Kirby A, Lewis DA, Marschner I, Pollicino C, Reith C, Simes J, Sourjina T

6. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015 Apr 11;385(9976):1397-405.

Collaborators (137)

Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A, de Lemos J, Braunwald E, Blazing M, Murphy S, Downs JR, Gotto A, Clearfield M, Holdaas H, Gordon D, Davis B, Koren M, Dahlöf B, Poulter N, Sever P, Knopp RH, Fellström B, Holdaas H, Jardine A, Schmieder R, Zannad F, Goldbourt U, Kaplinsky E, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Fuller J, Neil A, Wanner C, Krane V, Sacks F, Moyé L, Pfeffer M, Hawkins CM, Braunwald E, Kjekshus J, Wedel H, Wikstrand J, Barter P, Keech A, Tavazzi HF, Maggioni A, Tognoni RM, Franzosi MG, Maggioni A, Bloomfield H, Robins S, Collins R, Armitage J, Keech A, Parish S, Peto

R, Sleight P, Pedersen TR, Ridker PM, Holman R, Meade T, Simes J, Keech A, MacMahon S, Marschner I, Tonkin A, Shaw J, Serruys PW, Nakamura H, Knatterud G, Furberg C, Byington R, Macfarlane P, Cobbe S, Ford I, Murphy M, Blauw GJ, Packard C, Shepherd J, Kjekshus J, Pedersen T, Wilhelmsen L, Braunwald E, Cannon C, Murphy S, Collins R, Armitage J, Bowman L, Parish S, Peto R, Sleight P, Baigent C, Landray M, Collins R, La Rosa J, Rossouw J, Probstfield J, Shepherd J, Cobbe S, Macfarlane P, Ford I, Flather M, Kastelein J, Newman C, Shear C, Tobert J, Varigos J, White H, Yusuf S, Barnes EH, Keech AC, Kirby A, Marschner IC, Simes J, Baigent C, Blackwell L, Collins R, Emberson J, Herrington WG, Holland LE, Mihaylova B, Reith C.

Reviews, Books, Book Chapters, and Other Publications

1. Kleinberg DL and Newman CB. The pituitary gland in primate development: evidence that prolactin is not essential In: Angeli, A., Bradlow, H.L., and Godlotti, L. (eds). Endocrinology of the Breast: Basic and Clinical Aspects. Annals of the New York Acad Sci 1986; Vol. 464, pages 37-43.
2. Kleinberg DL, Newman CB, and Feldman M. Role of the pituitary in mammary development. In: Melmed S and Robbins R (eds.) Molecular and Clinical Advances in Pituitary Disorders. 1990. Blackwell Scientific Publications, Oxford, pp.195-200.
3. Newman CB and Kleinberg DL. Preoperative endocrinologic evaluation of the patient with a nonsecreting pituitary tumor. In: Cooper PR (ed.) Contemporary Diagnosis and Management of Pituitary Adenomas. 1991. American Association of Neurologic Surgeons, Park Ridge, Illinois, pp. 21-28.
4. Newman CB and Kleinberg DL. Acromegaly: how do you define cure? In: Cooper PR (ed.) Contemporary Diagnosis and Management of Pituitary Adenomas. 1991. American Association of Neurological Surgeons, Park Ridge, Illinois, pp. 47-52.
5. Weintraub HS, Field S, Hymes K, Newman CB and Kleinberg DL. The perioperative medical evaluation of neurosurgical patients. In: Tindall GT, Cooper PR, and Barrow DL (eds) The Practice of Neurosurgery. 1995. Williams & Wilkins, Baltimore, MD, pp. 251-269.
6. Newman CB. Long-term management of acromegaly. In: Clinical Endocrinology Update 1996, The Endocrine Society Press, Bethesda MD, pp. 43-55.
7. Newman CB. Acromegaly. In: Bardin CW (ed.) Current therapy of Endocrinology and Metabolism. 1997, sixth edition. Mosby-Year Book, Inc., Philadelphia, PA., pp. 47-51.
8. Newman CB and Kleinberg DL. Adult Growth Hormone Deficiency. The Endocrinologist 1998; 8: 178 -186.
9. Newman CB. Medical therapy for acromegaly. In Advances in Pituitary Tumor Therapy. Endocrinology and Metabolism Clinics of North America. 1999; Volume 28.
10. Newman CB. Acromegaly. In Molitch M (ed.), Atlas of Clinical Endocrinology, Volume 4 Neuroendocrinology and Pituitary Disease. 2000. Current Medicine Inc., Philadelphia PA.
11. Newman CB. Pharmacological treatment for sexual problems: The Benefits Outweigh the Risks. In Taverner B and McKee R (eds.) Taking Sides: Clashing Views in Human Sexuality, 12th ed., Mc-Graw Hill, 2011.

12. Newman CB. Statin intolerance. Management of hyperlipidemia in the statin-intolerant patient. Meet the Professor Endocrine Case Management 2015-ebook; The Endocrine Society; pages 102-113.

13. Newman C and Tobert J. Safety and Tolerability of Lipid Lowering Medication. In Myerson M (editor), Dyslipidemia: A Clinical Approach, Wolters Kluwer, 2018, pages

14. Newman CB and Tobert JA. Statin-Related Myopathy and Rhabdomyolysis. In Matfin G (editor) Endocrine and Metabolic Emergencies: A Clinician's Guide, second edition. John Willey and Sons, Ltd, Chicester UK, 2018, pages 760-774.

15. Newman C. *Five Things to Know about Statin Safety and the Nocebo Effect*. Medscape Diabetes. WebMD LLC (published online March 2017)

Abstracts Presented at National and International Meetings

1. Newman CB, Wardlaw SL, and Frantz AG. ACTH 19-39 (CLIP) suppresses prolactin and stimulates LH secretion. Clin Res 1984; 32:271A.

2. Newman CB, Cosby H, Friesen H, Stampfer M, Monaco ME, and Kleinberg DL. Novel human pituitary factors stimulate growth of mammary cancer cells and normal mammary gland. Clin Res 1986; 34: 645A.

3. Newman CB, Boyett RL, and Kleinberg DL. CV 205-502: a long-acting dopamine agonist for the treatment of hyper-prolactinemia. September 13-16, 1987; 4th European Workshop on Pituitary Adenomas, Zurich, Switzerland.

4. Feldman M, Newman CB, and Kleinberg DL. Growth hormone is a more potent mammary mitogen than prolactin in vivo. Clin Res 1990; 38:343A.

5. Newman CB, Aronoff L, and Feldman M. Effects of growth hormone and prolactin on mammary development in hypophysectomized rhesus monkeys. 72nd Annual Meeting of the Endocrine Society, June 20-23, 1990, Atlanta, Georgia, Abstract 909.

6. The GH-Deficient Adult Study Group. GH therapy in adults with acquired GH deficiency: a double blind, randomized, placebo controlled one year intervention trial. 77th Annual Meeting of the Endocrine Society, June 14-17, 1995, Washington, DC, Abstract P2-264.

7. Vance ML, Woodburn CJ, Putney S, Grous J, Lee HJ, Johnson OL, Kleinberg DL, Kidder T, Newman CB. Effects of sustained release growth hormone on serum GH, IGF-I, and IGFBP-3 concentrations in GH deficient adults. Second International Meeting of the Growth Hormone Research Society, November 13-16, 1996, London.

8. Growth Hormone Deficient Adult Study Group, Genentech Inc. Baseline abnormalities of body composition are more severe in adults with childhood-onset growth hormone deficiency.

79th Annual Meeting of the Endocrine Society, June 11-14, 1997, Minneapolis, MN, Abstract OR 29-1.

9. Newman C, Hopkinson C, Messig, M, Silbershatz H, Palmer G. Efficacy of atorvastatin in dyslipidemic patients with metabolic syndrome in the ACCESS study. 63rd Meeting of the American Diabetes Association, June 13-17, 2003, New Orleans, Abstract 2140.

10. Newman C, Hopkinson C, Silbershatz H, Hey-Hadavi J, Palmer G. Comparison of the efficacy and safety of atorvastatin and simvastatin in dyslipidemic patients with metabolic syndrome in the ASSET study. 85th Annual Meeting of the Endocrine Society, June 19-22, 2003, Philadelphia, PA, Abstract 548.

11. Newman CB, Tsai J, Gibson E, Szarek M. Muscle-related adverse effects are comparable with atorvastatin versus placebo in 1660 patients. 15th International Symposium of Drugs Affecting Lipid Metabolism. October 24-28, 2004, Venice, Italy.

12. Hitman GA, Newman CB, Szarek M, Colhoun HM, Betteridge DJ, Durrington PN, Neil HAW, Livingstone S, Fuller JH on behalf of the CARDS Investigators. Effect of Atorvastatin on Stroke in Patients with Type 2 Diabetes: Factors Predicting the Risk of Stroke in the Collaborative Atorvastatin Diabetes Study (CARDS). 41st European Association for the Study of Diabetes Meeting, September 10-15, 2005, Athens, Greece.

13. Newman CB, Szarek M, Hitman GA, Colhoun HM, Betteridge DJ, Durrington PN, Neil HAW, Livingstone S, Fuller JH. Effect of Atorvastatin on Stroke in the Collaborative Atorvastatin Diabetes Study (CARDS): Factors Predictive of the Risk of Stroke. American Heart Association 2005 Scientific Sessions, November 13-16, Dallas Texas.

14. Hitman GA, Newman C, Szarek M, Colhoun HM, Betteridge DJ, Durriington PN, Neil A, Livingston SJ, Fuller JH. Stroke in Patients with Type 2 Diabetes: Further Analysis of the Collaborative Atorvastatin Diabetes Study (CARDS). 88th Annual Meeting of the Endocrine Society, June 24-27, 2006, Boston, Mass, Abstract P2-799.

15. Newman C, Szarek M, DeMicco D, Hitman GA, Colhoun HM, Betteridge DJ, Durrington PN, Neil HA, Livingston SJ, Fuller JH. Safety of atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). 88th Annual Meeting of the Endocrine Society, June 24-27, 2006, Boston, Mass, Abstract P3-685.

16. Frisch K, Newman CB, Rosenzweig B, Roubenoff R, Rey M, Kidder T, Kong Y, Schwartzbard A, Kleinberg, D. Are Currently Employed Growth Hormone Doses Sufficient to Provide Cardiovascular Benefits in Growth Hormone Deficient Adults? 91st Annual Meeting of the Endocrine Society, 2009.

17. Ahmad Z, Newman C, O'Brien E C, Shrader P, DeGoma EM, Ahmed CD, Moriarty PM, MacRae FL, Shapiro MD, Duell PB, Ballantyne CM, Neal WA, Duffy D, Hudgins LC, Hemphill L, Underberg, Watson KE, Gidding SS, Baum SJ, Wilemon K, Pickhardt D, Kindt I, Rader DJ, Roe MT, Knowles JW. Diagnosing Familial Hypercholesterolemia (FH) in the

United States: Results from the CASCADE FH Patient Registry. 97th Annual Meeting of the Endocrine Society, San Diego, California, March 5-8, 2015.

18. Newman CB, Clarke R, Hin H, Tomson J, Kurien R, Lay M, Sayer J, Hill M, Emberson J, Armitage J. Estimation of the Optimum Dose of Vitamin D for Older People: Results of the BEST-D Trial. 97th Annual Meeting of the Endocrine Society, San Diego, California, March 5-8, 2015.

19. deGoma E, Ahmad ZS, O'Brien E, Kindt I, Shrader P, Newman CB, Pokharel Y, Rader DJ, Moriarty PM, Gidding SS, Duell PB, Shapiro MD, Linton MF, Ballantyne CM, Duffy D, Baum SJ, Hemphill LC, Neal WA, Hudgins LC, Ahmed CD, Wilemon KA, Row MT, Knowles JW. LDL-C levels and treatment patterns among adults with heterozygous familial hypercholesterolemia in the United States: Data from the CASCADE-FH registry. American Heart Association Scientific Sessions, Orlando, Florida, November 7-11, 2016.

20. Newman CB, Tobert VJ, Saunders KH, Kumar RB. Innovative Solutions for the Prevention and Treatment of Obesity. Centennial Meeting of British Medical Women's Federation, London, May 10-13, 2017

21. Newman CB, Tobert VJ, Saunders KH, Kumar RB. Solutions for the Prevention and Treatment of Obesity in Adult Men and Women. Women's Healthcare Innovation Leadership Showcase, Rutgers University, Piscataway, NJ, June 14, 2017

22. Newman C and Kumar R. Sex Differences in Obesity. Centennial Meeting of the Medical Women's International Association. NY, NY July 25-28, 2019

23. Newman C, Kushner R, Horn DB. Development of Competencies to Promote Comprehensive Obesity Medicine Education across Undergraduate and Graduate Medical Education and Fellowship Training. Accepted for 26th European Congress of Obesity, Glasgow, Scotland, April 28-May 1, 2019

Opinion-Editorials

1. Opioid Addiction in Women: Help Women Avoid Dangers of Opioid Addiction, by Connie Newman and Kim Templeton. Published in The Hill August 28, 2018